Compare ACRV & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRV | CMCM |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.0M | 88.8M |
| IPO Year | 2022 | 2014 |
| Metric | ACRV | CMCM |
|---|---|---|
| Price | $1.73 | $2.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 216.5K | 7.5K |
| Earning Date | 11-12-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $23.52 |
| Revenue Next Year | N/A | $19.21 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $2.13 |
| 52 Week High | $3.56 | $9.00 |
| Indicator | ACRV | CMCM |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 52.40 |
| Support Level | $1.63 | $2.61 |
| Resistance Level | $2.21 | $3.45 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 20.45 | 58.63 |
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The companies products and services includes Robotic Products, Global to B Services etc. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC.